Kenneth Aldrich, Chairman and Chief Executive Officer of International Stem Cell Corporation (ISCO.OB) is speaking at Stem Cells USA & Regenerative Medicine Congress on the topic of "Is there a correct business model for regenerative medicine?" and is pleased to extend a 15% discount on your registration.
Be among the following already registered to attend:
Biotec GmbH; WuXi AppTec, Inc; Healthpoint, Ltd.; University of Nebraska Medical Center; Lonza Walkersville; LifeCell Corporation; Sartorius Stedim Biotech; Baxter Healthcare Corporation; Roche; Biomade; ECBio Sa; Medeia Therapeutics Ltd; ECBio Sa; Manufacturing Technology; BD Technologies; Miltenyi Biotec GmbH; Aastrom Biosciences; BD; NFCR; Mars Innovation; Pfizer; Tarix Pathfinder Pharmaceuticals; Vitrolife Sweden AB; AstraZeneca R&D; University of Minnesota; American Type Culture Collection; Advenced Technologies & Regenerative Medicine LLC; Invetech, Inc; Medrad, Inc; Cytograft;Theregen;GliaMed,Inc.; Roche; Txcell; BioTime;Stem Cell Therapeutics Corp.; Centocor;Cellerant Therapeutics; Genzyme; Darpha; Safeguard Scientifics; Wake Forest Institute for Regenerative Medicine; Novitas Capital; Baxter; Bay City Capital; Fate Therapeutics;Cell Seed;Proteus Venture Partners; TVM Capital; Organogenesis; The Havard Stem Cell Institute; National Institute of Health; CONNECT; Bioengineering Institute;Stratatech Corporation; Angioblast; Pfizer;Harvard Stem Cell Institute; Cellerix; Merck Research Laboratories; Athersys, Inc.; Advanced BioHealing; Tengion; Food and Drug Administration Center for Biologics Evaluation and Research; Juventas Therapeutics Inc.; Harvard Medical School; Haecker Consulating; University of Pittsburgh School of Medicine; International Stem Cell Corporation (ISCO.OB);Pervasis Therapeutics; GliaMed, Inc.; Novocell; California Stem Cell; University of Minho; Garnet BioTherapeutics; Athersys, Inc.; Drexel University College of Medicine; Advanced BioHealing; Johnson & Johnson; Panacea Biotec Limited and more!